The global obesity epidemic has prompted significant interest and investment in developing and marketing obesity drugs. With millions worldwide struggling to manage their weight, it’s no surprise that pharmaceutical companies see this as a potentially lucrative market. However, the question arises: Is the market for obesity drugs overvalued? Several factors suggest caution is warranted when evaluating the prospects of obesity drugs.